Teijin Pharma Limited and TransThera jointly announced that they have entered into a strategic collaboration agreement for joint research and development of the innovative drugs in the target fields of oncology and inflammatory diseases.

-- 続きを読む (英語) --

Nanjing, China, October 29th, 2020--TransThera Biosciences announces today the Investigational New Drug (IND) application of TT-00420 for the indication of cholangiocarcinoma (CCA) has been submitted to Food and Drug Administration (FDA) in the United States.

-- 続きを読む (英語) --

Seoul, South Korea and Nanjing, China – LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences jointly announce today the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.

-- 続きを読む (英語) --

NANJING, China, and SEOUL, Korea, August 18th, 2020 – LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that LG Chem has entered an exclusive license agreement with TransThera, for the development and commercialization of TransThera’s TT-01025, a highly selective oral small molecule inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) that has shown promising efficacy in pre-clinical investigation in non-alcoholic steatohepatitis (NASH). TT-01025 is expected to enter Phase I trial in early 2021 in the US.

-- 続きを読む (英語) --

NANJING, China, March 7, 2020 -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, today announced that the first cohort of healthy volunteers has been dosed in Phase 1 clinical trial with TT-00920, a novel Phosphodiesterase 9 (PDE 9) inhibitor in development for the treatment of chronic heart failure.

-- 続きを読む (英語) --

NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for TT-00920, a novel small molecule inhibitor of Phosphodiesterase 9 (PDE 9) for the treatment of chronic heart failure.

-- 続きを読む (英語) --

NANJING, China, Nov. 6, 2019 / -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma.

-- 続きを読む (英語) --

NANJING, China, March 2nd, 2019 TransThera Biosciences Co. Ltd today announced that it has initiated preclinical development of its proprietary lead compound TT-00920. TT-00920 is a first-in-class, orally bioavailable drug candidate for the treatment of heart failure disease. “The advancement of TT-00920 into preclinical development is an important milestone for TransThera. Compelling preclinical results support that TT-00920 can improve cardiac function in both HFrEF (heart failure with reduced ejection fraction) and HFpEF (heart failure with preserved ejection fraction). We hope to bring a breakthrough therapy to patients suffering from this severe disease with our innovative drug. " said Dr. Frank Wu, founder and CEO of TransThera. The company expects to submit INDs in the US in the fourth quarter of 2019.

-- 続きを読む (英語) --

TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).

-- 続きを読む (英語) --